Early Use of Two Asthma Meds Could Prevent Lethal Pneumonia

Share this content:
Early Use of Two Asthma Meds Could Prevent Lethal Pneumonia
Early Use of Two Asthma Meds Could Prevent Lethal Pneumonia

MONDAY, Feb. 27, 2017 (HealthDay News) -- Two medications used to treat asthma and allergies may help prevent a particularly dangerous form of pneumonia caused by influenza A virus (IAV) infection, according to a study published online recently in PLOS Pathogens.

In an effort to examine the contribution of alveolar macrophages in regulating the severity of IAV infection, Amber Cardani, Ph.D., from the Beirne B. Carter Center for Immunology Research at the University of Virginia in Charlottesville, and colleagues employed a murine model in which the Core Binding Factor Beta gene is conditionally disrupted in myeloid cells.

The researchers found that these mice exhibit a selective deficiency in alveolar macrophages; the deficient mice developed severe diffuse alveolar damage, lethal respiratory compromise, and consequent lethality following IAV infection. In these mice, lethal injury resulted from increased infection of type-1 alveolar epithelial cells (T1AECs) and the elimination of infected T1AEC by the adaptive immune T-cell response. Further analysis indicated suppression of the cysteinyl leukotriene (cysLT) pathway genes in T1AECs mediated by alveolar macrophages in vivo and in vitro. In a T1AEC cell line, inhibition of the cysLT pathway enzymes reduced the susceptibility of T1AECs to IAV infection. Inhibition of the cysLT pathway enzymes and blockade of the cysteinyl leukotriene receptors in alveolar macrophage-deficient mice correlated with reduced susceptibility of their T1AECs to IAV infection and protection from lethal infection.

"The excitement of this is the possibility of someone coming to see the physician with influenza that looks a little more severe than usual and treating them with the drugs Singulair or Accolate and preventing them from getting severe pneumonia," a coauthor said in a news release.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »